3 completed, 1 unknown. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow COPD Exacerbation: new trials by email Literature Review of COPD Exacerbation trials Research Report on COPD Exacerbation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD Tezepelumab, Placebo - COPD, COPD Exacerbation | Phase 2 | Unknown | Asger Sverrild | 80 | 2022-10-25 | 2024-08-21 |
| Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP) MSTT1041A, Placebo - COPD Exacerbation | Phase 2 | Completed | University of Leicester | 81 | 2018-10-11 | 2022-06-21 |
| Extracorporeal CO2 Removal in COPD Exacerbation minimally invasive extracorporeal carbon dioxide removal - COPD Exacerbation | Phase 2 | Completed | University of Turin, Italy | 30 | 2011-05-01 | 2014-01-22 |
| TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial Prednisone, Etanercept, levofloxacin - COPD Exacerbation | Phase 2 / Phase 3 | Completed | Ottawa Hospital Research Institute | 81 | 2008-11-01 | 2016-04-11 |
Pulmonary Disease, Chronic Obstructive (3) · Immune System Diseases (1)
Chronic Disease (3) · Disease Attributes (3) · Lung Diseases (3) · Lung Diseases, Obstructive (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Respiratory Tract Diseases (3)
Etanercept (1) · Levofloxacin (1) · Prednisone (1) · astegolimab (1) · tezepelumab (1)
Asger Sverrild (1) · Ottawa Hospital Research Institute (1) · University of Leicester (1) · University of Turin, Italy (1)
United Kingdom (2) · Denmark (1) · Italy (1)
Asger Sverrild, MD, PhD (1) · Christopher Brightling, Prof (1) · Shawn Aaron, MD, MSc (1) · V. Marco Ranieri, MD (1)
PMID 23161645, PMID 25230375, PMID 35339234
2018 (1)